These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 28927298

  • 1. Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up.
    Kaufmann S, Thaiss WM, Schulze M, Bitzer M, Lauer U, Nikolaou K, Horger M.
    Acta Radiol; 2018 Jul; 59(7):765-772. PubMed ID: 28927298
    [Abstract] [Full Text] [Related]

  • 2. Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study.
    Sacco R, Faggioni L, Bargellini I, Ginanni B, Battaglia V, Romano A, Bertini M, Bresci G, Bartolozzi C.
    Dig Liver Dis; 2013 Sep; 45(9):776-81. PubMed ID: 23578581
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Ippolito D, Querques G, Pecorelli A, Talei Franzesi C, Okolicsanyi S, Strazzabosco M, Sironi S.
    J Comput Assist Tomogr; 2019 Sep; 43(2):206-213. PubMed ID: 30407241
    [Abstract] [Full Text] [Related]

  • 4. Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study.
    Ippolito D, Querques G, Okolicsanyi S, Franzesi CT, Strazzabosco M, Sironi S.
    Eur J Radiol; 2017 May; 90():34-41. PubMed ID: 28583645
    [Abstract] [Full Text] [Related]

  • 5. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
    Gavanier M, Ayav A, Sellal C, Orry X, Claudon M, Bronowicki JP, Laurent V.
    Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
    [Abstract] [Full Text] [Related]

  • 6. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
    Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, Le Roux C, Raoul JL.
    Cancer; 2012 Jan 01; 118(1):147-56. PubMed ID: 21713764
    [Abstract] [Full Text] [Related]

  • 7. Decrease in tumor enhancement on contrast-enhanced CT is associated with improved survival in patients with hepatocellular carcinoma treated with Sorafenib.
    Patchett N, Furlan A, Marsh JW.
    Jpn J Clin Oncol; 2016 Sep 01; 46(9):839-44. PubMed ID: 27317737
    [Abstract] [Full Text] [Related]

  • 8. Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results.
    Salvaggio G, Furlan A, Agnello F, Cabibbo G, Marin D, Giannitrapani L, Genco C, Midiri M, Lagalla R, Brancatelli G.
    Radiol Med; 2014 Apr 01; 119(4):215-21. PubMed ID: 24297581
    [Abstract] [Full Text] [Related]

  • 9. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
    Wang W, Bai W, Wang E, Zhao Y, Liu L, Yang M, Cai H, Xia D, Zhang L, Niu J, Yin Z, Zhang Z, Fan D, Xia J, Han G.
    Int J Cancer; 2017 Jan 15; 140(2):390-399. PubMed ID: 27681592
    [Abstract] [Full Text] [Related]

  • 10. Hepatocellular carcinoma treated with sorafenib: Arterial tumor perfusion in dynamic contrast-enhanced CT as early imaging biomarkers for survival.
    Nakamura Y, Kawaoka T, Higaki T, Fukumoto W, Honda Y, Iida M, Fujioka C, Kiguchi M, Aikata H, Chayama K, Awai K.
    Eur J Radiol; 2018 Jan 15; 98():41-49. PubMed ID: 29279169
    [Abstract] [Full Text] [Related]

  • 11. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S.
    Oncologist; 2014 Apr 15; 19(4):394-402. PubMed ID: 24652387
    [Abstract] [Full Text] [Related]

  • 12. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
    Meyer T, Palmer DH, Cheng AL, Hocke J, Loembé AB, Yen CJ.
    Liver Int; 2017 Jul 15; 37(7):1047-1055. PubMed ID: 28066978
    [Abstract] [Full Text] [Related]

  • 13. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.
    Sugimoto K, Moriyasu F, Saito K, Rognin N, Kamiyama N, Furuichi Y, Imai Y.
    Liver Int; 2013 Apr 15; 33(4):605-15. PubMed ID: 23305331
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
    Kloth C, Thaiss WM, Kärgel R, Grimmer R, Fritz J, Ioanoviciu SD, Ketelsen D, Nikolaou K, Horger M.
    Acad Radiol; 2017 Nov 15; 24(11):1352-1363. PubMed ID: 28652049
    [Abstract] [Full Text] [Related]

  • 15. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
    Takada J, Hidaka H, Nakazawa T, Kondo M, Numata K, Tanaka K, Matsunaga K, Okuse C, Kobayashi S, Morimoto M, Ohkawa S, Koizumi W.
    BMC Res Notes; 2015 Oct 26; 8():609. PubMed ID: 26502722
    [Abstract] [Full Text] [Related]

  • 16. Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?
    Bargellini I, Scionti A, Mismas V, Masi G, Vivaldi C, Bartolozzi C, Sacco R.
    Oncology; 2014 Oct 26; 86(4):191-8. PubMed ID: 24800837
    [Abstract] [Full Text] [Related]

  • 17. Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results.
    Frampas E, Lassau N, Zappa M, Vullierme MP, Koscielny S, Vilgrain V.
    Eur J Radiol; 2013 May 26; 82(5):e205-11. PubMed ID: 23273822
    [Abstract] [Full Text] [Related]

  • 18. Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib.
    Tovoli F, Renzulli M, Negrini G, Brocchi S, Ferrarini A, Andreone A, Benevento F, Golfieri R, Morselli-Labate AM, Mastroroberto M, Badea RI, Piscaglia F.
    Eur Radiol; 2018 Sep 26; 28(9):3611-3620. PubMed ID: 29633000
    [Abstract] [Full Text] [Related]

  • 19. Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions.
    Ippolito D, Querques G, Okolicsanyi S, Talei Franzesi C, Pecorelli A, Lombardi S, Orsini E, Strazzabosco M, Sironi S.
    Eur J Radiol; 2018 Sep 26; 106():62-68. PubMed ID: 30150052
    [Abstract] [Full Text] [Related]

  • 20. Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.
    Zocco MA, Garcovich M, Lupascu A, Di Stasio E, Roccarina D, Annicchiarico BE, Riccardi L, Ainora ME, Ponziani F, Caracciolo G, Rapaccini GL, Landolfi R, Siciliano M, Pompili M, Gasbarrini A.
    J Hepatol; 2013 Nov 26; 59(5):1014-21. PubMed ID: 23811306
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.